AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Anglo-Swedish firm already had a strong lineup of cancer drugs when vaccine success gave it a further boost

AstraZeneca set to weather Covid in better health than rivals

NEW YORK--(BUSINESS WIRE)--WHY: New York, N.Y., February 5, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"), of the important March 29, 2021 lead plaintiff deadline. SO WHAT: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingen

BREAKING ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AstraZeneca PLC Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline – AZN

The coming week will see yet more big name firms updating from a variety of sectors including pharmaceuticals, travel and grocery. Investors will also be looking across the Atlantic again, with earnings data expected across the pond from a number of major players including Disney, Coca-Cola, and Uber.

AstraZeneca, TUI, Ocado, Royal Mail among key updates for coming week, UK GDP eyed

The coronavirus vaccine developed by AstraZeneca and Oxford University has the same level of efficiency against the new Covid variant, according to new data Friday.

AstraZeneca-Oxford vaccine works against Covid variant found in the UK, data shows

AstraZeneca Plc (NASDAQ: AZN) has reported that a Phase 3 KESTREL trial testing Imfinzi (durvalumab) as the first-line treatment of head and neck cancer did not meet the primary endpoint of improving overall survival, compared to the EXTREME treatment regimen (chemotherapy plus cetuximab), a standard of care. “We will continue to build on the established benefits of Imfinzi in early lung cancer and small cell lung cancer, to bring immunotherapy treatment options to all patients who may benefit,” said Dave Fredrickson, head of oncology.

AstraZeneca's Imfinzi Fails To Prolong Survival In Late-Stage Head And Neck Cancer Study

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired AstraZeneca securities between May 21, 2020 and November 20, 2020, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/azn. Th

AZN Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies AstraZeneca PLC Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Pfizer

According to Reuters, the United Kingdom has launched a pioneering clinical study to test whether alternating the AstraZeneca Plc (NASDAQ: AZN), and Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccines in a two-shot schedule is safe and effective in fighting the infection.

UK To Test Combining Pfizer And AstraZeneca Vaccines In Two-Shot Regimen

New York, New York--(Newsfile Corp. - February 3, 2021) -  Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than...

Breaking Notice: Rosen, A Globally Recognized Law Firm, Encourages AstraZeneca PLC Investors with Large Losses to Secure Counsel Before Important Deadline - AZN

Rapidly spreading variants of Covid-19 are capable of reducing the efficacy of existing vaccines.

Next-Gen Vaccine For Covid-19 Mutants Will Be Ready By Fall, AstraZeneca Says

Switzerland, the only country in continental Europe, has declined to approve the Oxford and AstraZeneca Plc (NASDAQ: AZN) COVID-19 vaccine, citing lack of data for the vaccine, the Financial Times reports.

Switzerland Declines To Approve AstraZeneca COVID-19 Vaccine - Financial Times

SCOTTSDALE, Ariz., Feb. 3, 2021 /PRNewswire/ -- Matrix Medical Network® (Matrix) today announced a collaboration with global biopharmaceutical company AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca's long-acting monoclonal antibody (LAAB) combination for the...

Matrix Medical Network Collaborates with AstraZeneca on Phase III Clinical Trial for COVID-19 Long-Acting Antibody Combination

AstraZeneca and Oxford University have co-developed a "next generation" COVID-19 vaccine to tackle new coronavirus variants, and it could be available in the Autumn, its executive vice-president said Wednesday. "We're very much aiming to try and have something ready by the autumn, so this year," Mene Pangalos said, per Reuters.

AstraZeneca says it's developing a 'next generation' COVID-19 vaccine to target fast-spreading variants.

The researchers found that the AstraZeneca vaccine's efficacy was 76% after a first dose, rising to 82.4% once a second dose was given after 12 weeks.

AstraZeneca Vaccine May Reduce Virus Spread by 67%, Oxford Study Finds

Study appears to supports U.K. government's decision to delay second doses and vaccinate more people more quickly.

AstraZeneca vaccine may reduce spread by 67% — and protection remains over 3-month dosage gap

A second dose of the Oxford-AstraZeneca vaccine raises the vaccine's efficacy to 82.4% if it is administered after a 12-week gap.

AstraZeneca Vaccine Helps Slow Covid-19 Transmission, First Dose 76% Effective For At Least Three Months, Study Finds

The AstraZeneca-University of Oxford coronavirus vaccine can cut the spread of the virus and delaying the second dose works, according to a new study.

AstraZeneca vaccine can slow the spread of Covid and delayed second dose works, Oxford data shows

AbbVie

Gilead Sciences

Viatris

Bristol-Myers

Merck

Covid-19 vaccines are getting all the glory after multi-bagger returns last year but these seven pharmaceutical stocks have a strong future ahead. The post 7 Pharmaceutical Stocks With Compelling Pipelines appeared first on InvestorPlace.

7 Pharmaceutical Stocks With Compelling Pipelines

Warning of ‘legal commitment' and concern that doses might have been diverted from the EU to the UK

France and Germany threaten AstraZeneca over vaccine shortage

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class...

BREAKING NOTICE: ROSEN, A LEADING LAW FIRM, Encourages AstraZeneca PLC Investors with Large Losses to Secure Counsel Before Important Deadline - AZN

NEW YORK, Jan. 29, 2021 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors who purchased AstraZeneca PLC's American Depositary Shares ("ADSs") (NASDAQ: AZN) between May 21, 2020 and November 20, 2020 (the "Class Period"). A...

Investor Alert: Kaplan Fox Investigates Potential Securities Fraud At AstraZeneca PLC

LOS ANGELES--(BUSINESS WIRE)---- $AZN #CLASSACTION--Glancy Prongay & Murray LLP, Leading Securities Law Firm, Announces the Filing of Securities Class Action on Behalf of AstraZeneca PLC (AZN) Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of AstraZeneca PLC (AZN) Investors

European Medicines Agency decision comes despite Germany saying it will not recommend jabs for over-65s.

EU's drug regulator authorizes AstraZeneca COVID-19 vaccine for all ages over 18

The vaccine is already in use in the U.K., having been approved at the end of December, and now makes up the bulk of jabs being administered in the country.

AstraZeneca-Oxford vaccine approved for use by European regulator

The European Union is piling pressure on the drugmaker to deliver the Covid vaccine supplies it promised.

EU publishes AstraZeneca vaccine contract as battle over supplies heats up

Datadog

EverBank Financial

Exelixis

Growth stocks have run circles around value stocks for more than a decade, and that trend is likely to continue.

News for AstraZeneca Stock (AZN)